Fospropofol
Chemical compound
From Wikipedia, the free encyclopedia
Fospropofol (INN[3]), often used as the disodium salt (trade name Lusedra[4]), is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
liabilityunknown
Chemical structure of fospropofol disodium | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Dependence liability | unknown |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 98%[1] |
| Metabolism | Hepatic glucuronidation |
| Elimination half-life | 0.81 hours[1] |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21O5P |
| Molar mass | 288.280 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Clinical applications
Several water-soluble derivatives and prodrugs of the widely used intravenous anesthetic agent propofol have been developed, of which fospropofol has been found to be the most suitable for clinical development thus far.[5][6] Purported advantages of this water-soluble chemical compound include less pain at the site of intravenous administration, less potential for hyperlipidemia with long-term administration, and less chance for bacteremia.[citation needed] Often, fospropofol is administered in conjunction with an opioid such as fentanyl.[citation needed]
Clinical pharmacology
Mechanism of action
Fospropofol is a prodrug of propofol; as an organophosphate it is metabolized by alkaline phosphatases to phosphate and formaldehyde and the active metabolite, propofol.
Pharmacodynamics
Pharmacokinetics
Initial trial results on fospropofol pharmacokinetics were retracted by the investigators. As of 2011, new results were not available.[7]
Distribution
Following the administration of fospropofol 12.5 mg/kg (the maximum recommended dose) loss of consciousness takes about four minutes, compared to one arm-brain circulation time with propofol 2.5 mg/kg (the maximum recommended dose).[8]
Metabolism
Fospropofol is metabolized in the liver by alkaline phosphatases to propofol, formaldehyde, and phosphate. The hepatic metabolism of this prodrug to an active metabolite means that peak plasma levels of propofol after the administration of a bolus of fospropofol are lower than for an equipotent dose of propofol and also that its clinical effect is more sustained.[9][10] These features can be desirable for endoscopic procedures such as esophagogastroduodenoscopy, colonoscopy, bronchoscopy, as well as for some surgical procedures done under local or regional anesthesia.
Propofol is further metabolised to propofol glucuronide (34.8%) and quinol glucuronide.[11] Formaldehyde is a known carcinogen but label information states that serum formaldehyde levels are similar to background levels. No long term studies have been done on the cancer risks. The parent drug has a terminal elimination half-life of 0.88+/-0.08 hours, which is non-renal.[12]
Controlled substance
Fospropofol is classified as a Schedule IV controlled substance in the United States' Controlled Substances Act.[13]